Molecular testing of solid tumors

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 1, 2011, Pages 67-82

  Igbokwe, Anne ^a   Lopez Terrada, Dolores H ^b  

^a Molecular Pathology Laboratory   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER INVASION; CHROMOSOME ABERRATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; HUMAN; METASTASIS; MOLECULAR DIAGNOSIS; MUTATION; NEOPLASM; PATHOLOGY;

CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79251633533     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (166)

1. Huang WY, Sheehy TM, Moore LE, Hsing AW, Purdue MP. Simultaneous recovery of DNA and RNA from formalin-fixed paraffin-embedded tissue and application in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):973-977.
2. Baloglu G, Haholu A, Kucukodaci Z, Yilmaz I, Yildirim S, Baloglu H. The effects of tissue fixation alternatives on DNA content: a study on normal colon tissue. Appl Immunohistochem Mol Morphol. 2008,16(5):485-492.
3. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996; 2(7):811-814.
4. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.
5. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237(4811):178-182.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785).177-182.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-1672.
8. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29-36.
9. Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl) Med. 2007;357(15):1496-1506.
10. Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. 2008;100(1):14-20.
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354(8):809-820.
12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-1684.
13. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
14. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1 ): 92-98.
15. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007,131(1):18-43.
16. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323-1333.
17. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl lmmunohistochem Mol Morphol. 2009; 17(1 ):1-7.
18. Bartlett JM, Ibrahim M, Jasani B, et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J. Clin Pathol. 2007;60(7):816-819.
19. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003,199(4):411-417.
20. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001,195(4):422-428.
21. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissuebased detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000,18(21):3651-3664.
22. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291(16):1972-1977.
23. LaI P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121(5):631-636.
24. Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61 (7):818-824.
25. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004;5(2):105-116.
26. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology breast cancer. Version 2.2008. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed August 20, 2010.
27. Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998;77(7):1130-1136.
28. Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60(8):2155-2162.
29. Takahashi S, Moriya T, Ishida T, et al. Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sei. 2008;99(2):324-332.
30. Farshid G, Balleine RL, Cummings M, Waring P. Morphology of breast cancer as a means of triage of patients for BRCAI genetic testing. Am J Surg Pathol. 2006;30(11):1357-1366.
31. Nelson HD, Huffman LH, Fu R, Harris EL. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005;143(5):362-379.
32. ACOG committee opinion, breast-ovarian cancer screening, Number 239, August 2000, American College of Obstetricians and Gynecologists, committee on genetics. Int J Gynaecol Obstet. 2001;75(3):339-340.
33. American College of Medical Genetics. Genetic susceptibility to breast and ovarian cancer: assessment, counseling and testing guidelines. 1999. http:// www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm. Published 1999. Accessed August 20, 2010.
34. American Cancer Society. Colorectal cancer facts & figures 2008-2010. Atlanta: American Cancer Society, 2008. http://www.cancer.org/acs/groups/ content/αnho/documents/document/f861708finalforwebpdf.pdf. Accessed August 20, 2010.
35. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9(4):138-141.
36. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-2460.
37. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol. 2009;33(1):126-133.
38. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol. 2009;16(4):196-203.
39. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091-2096.
40. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
41. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999; 116(6):1453-1456.
42. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-2087.
43. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257.
44. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol. 2007;38(4):614-620.
45. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type Il receptor gene in colorectal cancer. Cancer Res. 1995;55(23):5548-5550.
46. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. ; Mol Diagn. 2008;10(1):13-27.
47. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344(16): 1196-1206.
48. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol. 1998,16(2):427-433.
49. Ogino S, Nosho K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009;27(27):4591-4598.
50. Fearnhead NS, Britten MP, Bodmer WF. The ABC of APC. Hum Mol Genet. 2001;10(7):721-733.
51. Croner RS, Guenther K, Foertsch T, et al. Tissue preparation for gene expression profiling of colorectal carcinoma: three alternatives to laser microdissection with preamplification. J Lab Clin Med. 2004;143(6):344-351.
52. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101(1):3-27.
53. Wistuba II, Gazdar AF. Characteristic genetic alterations in lung cancer. Methods Mol Med. 2003;74:3-28.
54. Hunt JL. Molecular testing in solid tumors: an overview. Arch Pathol Lab Med. 2008;132(2):164-167.
55. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
56. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676): 1497-1500.
57. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101(36):13306-13311.
58. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11(16):5878-5885.
59. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
60. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005;23(28):6838-6845.
61. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126(4):608-615.
62. Bubendorf L, Muller P, Joos L, et al. Multitarget FISH analysis in the diagnosis of lung cancer. Am J Clin Pathol. 2005, 23(4):516-523.
63. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
64. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-346.
65. Polgar D, Leisser C, Maier S, et al. Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K. Mutat Res. 2005;570(1):9-15.
66. Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J Natl Cancer Inst. 2010;102(10):672-675.
67. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
68. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007,131(6):1190-1203.
69. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15(9):3143-3149.
70. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALKpositive lung cancer. Proc Natl Acad Sci USA. 2008; 105(50):19893-19897.
71. Kwak EL, Camidge DR, Clark J, Shapiro Gl, Maki RG, Ratain MJ. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 [abstract]. J Clin Oncol. 2009:27(15)(suppl):3509.
72. Bang Y, Kwak EL, Shaw AT, Camidge DR, Lafrate AJ, Maki RG. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with nonsmall cell lung cancer (NSCLC) !abstract!. J Clin Oncol. 2010;28(18)(suppl): 3.
73. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174(2): 661-670.
74. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev. 2008;27(3):495-522.
75. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54(10):1716-1724.
76. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-1908.
77. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006; 103(7):2257-2261.
78. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-4452.
79. Chen Y, Zheng B, Robbins DH, et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer. 2007;120(7):1511-1517.
80. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297-306.
81. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9(4):227-247.
82. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322(1-2):8-28.
83. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625-627.
84. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22(41):6455-6457.
85. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology. 2004,145(12):5448-5451.
86. Collins BJ, Chiappetta G, Schneider AB, et al. RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J Clin Endocrinol Metab. 2002;87(8):3941-3946.
87. Roque L, Nunes VM, Ribeiro C, Martins C, Soares J. Karyotypic characterization of papillary thyroid carcinomas. Cancer. 2001,92(10):2529-2538.
88. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma !corrected!. Science. 2000;289(5483): 1357-1360.
89. Sarquis MS, Weber F, Shen L, et al. High frequency of loss of heterozygosity in imprinted, compared with nonimprinted, genomic regions in follicular thyroid carcinomas and atypical adenomas. J Clin Endocrinol Metab. 2006;91(1):262-269.
90. Weber F, Aldred MA, Morrison CD, et al. Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab. 2005;90(2):1149-1155.
91. Alberti L, Carniti C, Miranda C, Roccato E, Pierotti MA. RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol. 2003,195(2):168-186.
92. Enzinger FM, Weiss SW. Soft Tissue Tumors. 4th ed. St Louis, MO: Mosby; 2001.
93. Fletcher CDM, Unni K, Mertens F, eds. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002. World Health Organization Classification of Tumours; vol 5.
94. Matushansky I, Maki RG. Mechanisms of sarcomagenesis. Hematol Oncol Clin North Am. 2005; 19(3):427-449.
95. Unni K, Inwards C, Bridge J, Kindblom L, Wild L. Tumors of the Bones and Joints. Washington, DC: ARP Press; 2005.
96. Aurias A, Rimbaut C, Buffe D, Zucker JM, Mazabraud A. Translocation involving chromosome 22 in Ewing's sarcoma: a cytogenetic study of four fresh tumors. Cancer Genet Cytogenet. 1984;12(1):21-25.
97. Whang-Peng J, Triche TJ, Knutsen T, Miser J, Douglass EC, Israel MA. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med. 1984; 311(9):584-585.
98. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNAbinding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162-165.
99. Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer. 1992;5(4):271-277.
100. Sandberg AA, Bridge JA. Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet. 2000;123(1):1-26.
101. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6(2):146-151.
102. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol. 2001;14(5):506-514.
103. Turc-Carel C, Lizard-Nacol S, Justrabo E, Favrot M, Philip T, Tabone E. Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet. 1986;19(3-4):361-362.
104. Douglass EC, Shapiro DN, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol. 1993;21(2):83-87.
105. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 2004;64(16):5539-5545.
106. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3(2):113-117.
107. Barr FG, Qualman SJ, Macris MH, et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 2002;62(16):4704-4710.
108. Bridge JA, Liu J, Qualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310-321.
109. Gerald WL, Rosai J, Ladanyi M. Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WTI gene fusion of desmoplastic small round cell tumor. Proc Natl Acad Sci USA. 1995;92(4):1028-1032.
110. Ladanyi M, Gerald WL. Specificity of the EWS/WT1 gene fusion for desmoplastic small round cell tumour. J Pathol. 1996;180(4):462.
111. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSXI and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995,14(10):2333-2340.
112. de Leeuw B, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum Mol Genet. 1995;4(6): 1097-1099.
113. Kawai A, Woodruff J, Healey )H, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338(3):153-160.
114. Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23(30):7669-7675.
115. Shmookler BM, Enzinger FM, Weiss SW. Giant cell fibroblastoma: a juvenile form of dermatofibrosarcoma protuberans. Cancer. 1989;64(10):2154-2161.
116. Szollosi Z, Nemes Z. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases. J Clin Pathol. 2005;58(7):751-756.
117. Naeem R, Lux ML, Huang SF, Naber SP, Corson JM, Fletcher JA. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol. 1995; 147(6): 1553-1558.
118. Terrier-Lacombe MJ, Guillou L, Maire G, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data-a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2003; 27(1):27-39.
119. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COLI Al-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol. 2008;39(2):184-193.
120. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of plateletderived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20(17):3586-3591.
121. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866-873.
122. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28(10):1772-1779.
123. Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998; 58(22):5046-5048.
124. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998,18(2): 184-187.
125. Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12,0 5) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153(5): 1451-1458.
126. Schofield DE, Fletcher JA, Grier HE, Yunis EJ. Fibrosarcoma in infants and children: application of new techniques. Am J Surg Pathol. 1994;18(1):14-24.
127. Argani P, Fritsch M, Kadkol SS, Schuster A, Beckwith JB, Perlman EJ. Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol. 2000;13(1):29-36.
128. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet. 2004,155(1 ): 1-24.
129. Powers MP, Wang W-L, Hernandez VS, et al. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay [published online ahead of print June 25, 20101. Mod Pathol. doi:10.1038/modpathol.2010.118.
130. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNAbinding protein in human myxoid liposarcoma. Nature. 1993;363(6430):640-644.
131. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29(10)1340-1347.
132. Ordonez NG, Ro JY, Mackay B. Alveolar soft part sarcoma: an ultrastructural and immunocytochemical investigation of its histogenesis. Cancer. 1989;63(9):1721-1736.
133. Segal NH, Pavlidis P, Noble WS, et al. Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol. 2003; 21(9):1775-1781.
134. Bridge JA, Sreekantaiah C, Neff JR, Sandberg AA. Cytogenetic findings in clear cell sarcoma of tendons and aponeuroses: malignant melanoma of soft parts. Cancer Genet Cytogenet. 1991;52(1):101-106.
135. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet. 1993;4(4):341-345.
136. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma: a clinico-pathologic study of half a century. Cancer. 1989;63(1):1-13.
137. Heimann P, Devalck C, Debusscher C, Sariban E, Vamos E. Alveolar softpart sarcoma: further evidence by FISH for the involvement of chromosome band 17q25. Genes Chromosomes Cancer. 1998;23(2):194-197.
138. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48-57.
139. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179-192.
140. Sorensen PH, Liu XF, Delattre O, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagn Mol Pathol. 1993;2(3): 147-157.
141. Barr FG, Xiong QB, Kelly K. A consensus polymerase chain reactionoligonucleotide hybridization approach for the detection of chromosomal translocations in pediatric bone and soft tissue sarcomas. Am J Clin Pathol. 1995,104(6):627-633.
142. Hill DA, O'Sullivan MJ, Zhu X, et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol. 2002;26(8):965-977.
143. Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, Perry A. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol. 2006,19(1):1-8.
144. Desmaze C, Zucman J, Delattre O, Melot T, Thomas G, Aurias A. Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet. 1994;74(1):13-18.
145. Monforte-Munoz H, Lopez-Terrada D, Affendie H, Rowland JM, Triche TJ. Documentation of EWS gene rearrangements by fluorescence in-situ hybridization (FISH) in frozen sections of Ewing's sarcoma-peripheral primitive neuroectodermal tumor. Am J Surg Pathol. 1999;23(3):309-315.
146. Machado I, Noguera R, Pellin A, et al. Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RTPCR. Diagn Mol Pathol. 2009; 18(4): 189-199.
147. Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol. 2010;34(6):757-766.
148. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol. 2001;23(2):99-104.
149. Peter M, Magdelenat H, Michon J, et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer. 1995;72(1):96-100.
150. Toretsky JA, Neckers L, Wexler LH. Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst. 1995;87(5):385-386.
151. de Alava E, Kawai A, Healey JH, et al. EWS-FLII fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998,16(4):1248-1255.
152. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer. 2004; 100(5):1053-1058.
153. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851-857.
154. Libra M, Malaponte G, Navolanic PM, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle. 2005;4(10):1382-1384.
155. Dahl C, Guldberg P. The genome and epigenome of malignant melanoma. APMIS. 2007;115(10):1161-1176.
156. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies (review). Int J Oncol. 2009;34(6): 1481-1489.
157. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J. 2000;346(pt 3):561-576.
158. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
159. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec). J Cutan Pathol. 2006;33(4):280-285.
160. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009;8(8):2079-2085.
161. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009;22(11):1446-1456.
162. Platz A, Ringborg U, Hansson J. Hereditary cutaneous melanoma. Semin Cancer Biol. 2000;10(4):319-326.
163. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009;7:86.
164. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995,13(8):2094-2103.
165. Bishop JF, Tracey E, Glass P, Jelfs P, Roder D. Prognosis of sub-types of cancer of unknown primary (CUP) compared to metastatic cancer [abstract]. J Clin Oncol. 2007;2508) (suppl):21010.
166. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010; 134(2):216-224.